BR112023003423A2 - Inibidores de apol1 e métodos de uso destes - Google Patents
Inibidores de apol1 e métodos de uso destesInfo
- Publication number
- BR112023003423A2 BR112023003423A2 BR112023003423A BR112023003423A BR112023003423A2 BR 112023003423 A2 BR112023003423 A2 BR 112023003423A2 BR 112023003423 A BR112023003423 A BR 112023003423A BR 112023003423 A BR112023003423 A BR 112023003423A BR 112023003423 A2 BR112023003423 A2 BR 112023003423A2
- Authority
- BR
- Brazil
- Prior art keywords
- apol1
- methods
- tautomer
- inhibitors
- ndrd
- Prior art date
Links
- 102100030762 Apolipoprotein L1 Human genes 0.000 title abstract 2
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 2
- 101710194425 Dehydrogenase/reductase SDR family member 4 Proteins 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000038001 non-diabetic kidney disease Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070705P | 2020-08-26 | 2020-08-26 | |
| PCT/US2021/047754 WO2022047031A1 (en) | 2020-08-26 | 2021-08-26 | Inhibitors of apol1 and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003423A2 true BR112023003423A2 (pt) | 2023-03-21 |
Family
ID=77822053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003423A BR112023003423A2 (pt) | 2020-08-26 | 2021-08-26 | Inibidores de apol1 e métodos de uso destes |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11866446B2 (https=) |
| EP (1) | EP4204423A1 (https=) |
| JP (2) | JP7743504B2 (https=) |
| KR (1) | KR20230057386A (https=) |
| CN (1) | CN116547287B (https=) |
| AR (1) | AR123355A1 (https=) |
| AU (1) | AU2021333776A1 (https=) |
| BR (1) | BR112023003423A2 (https=) |
| CA (1) | CA3190609A1 (https=) |
| CL (1) | CL2023000536A1 (https=) |
| CO (1) | CO2023003026A2 (https=) |
| CR (1) | CR20230132A (https=) |
| DO (1) | DOP2023000042A (https=) |
| EC (1) | ECSP23020167A (https=) |
| IL (2) | IL318169A (https=) |
| JO (1) | JOP20230035A1 (https=) |
| MX (1) | MX2023002269A (https=) |
| PE (1) | PE20231106A1 (https=) |
| SA (1) | SA523442662B1 (https=) |
| UY (1) | UY39395A (https=) |
| WO (1) | WO2022047031A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN116547287B (zh) * | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) * | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| CA3251050A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| WO2024249252A1 (en) * | 2023-05-26 | 2024-12-05 | Maze Therapeutics, Inc. | Methods of using apol1 inhibitors |
| AU2024343017A1 (en) | 2023-09-11 | 2026-03-19 | Vertex Pharmaceuticals Incorporated | Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran] -4'-ol |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039676A (en) | 1975-06-23 | 1977-08-02 | Ciba-Geigy Corporation | 2-piperidinoalkyl-1,4-benzodioxans |
| US6518423B1 (en) | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| AU7514700A (en) | 1999-09-07 | 2001-04-10 | Syngenta Participations Ag | Cyanopiperidines |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| US20030119060A1 (en) | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| WO2003104180A1 (en) | 2002-06-05 | 2003-12-18 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
| JP2007504221A (ja) | 2003-09-03 | 2007-03-01 | ガラパゴス・エヌブイ | 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用 |
| BRPI0507657A (pt) | 2004-03-03 | 2007-07-10 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| JP5406722B2 (ja) | 2006-10-16 | 2014-02-05 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体 |
| BRPI0721138A2 (pt) | 2006-12-22 | 2014-04-01 | Hoffmann La Roche | Derivados de espiro-piperidina |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| DK2178870T3 (en) | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| UA107943C2 (xx) | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| AU2010319400B2 (en) | 2009-11-16 | 2013-12-19 | Eli Lilly And Company | Spiropiperidine compounds as ORL-1 receptor antagonists |
| WO2012025155A1 (en) | 2010-08-26 | 2012-03-01 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases |
| BR102012024778A2 (pt) | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
| EP3186225A4 (en) | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| US10654838B2 (en) | 2014-10-08 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aminopyridine compounds useful as inhibitors of protein prenylation |
| JP2017535545A (ja) | 2014-11-21 | 2017-11-30 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物 |
| HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
| WO2017137334A1 (en) | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3787669A4 (en) | 2018-04-30 | 2022-03-30 | The Trustees of Indiana University | COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES |
| US11618746B2 (en) * | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| US20220144838A1 (en) | 2019-03-13 | 2022-05-12 | Nanjing Immunophage Biotech Co., Ltd. | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| TW202136219A (zh) | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| US20210246121A1 (en) | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| IL296423A (en) | 2020-04-22 | 2022-11-01 | Anima Biotech Inc | Collagen 1 translation inhibitors and methods of use thereof |
| WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
| JP2023524563A (ja) | 2020-05-07 | 2023-06-12 | ラムバム メド－テック リミテッド | Ａｐｏｌ１－関連疾患の治療に使用するための組成物 |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867532A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| CN115996923B (zh) | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US20230119114A1 (en) | 2021-08-26 | 2023-04-20 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitors and methods of using same |
| EP4440697A1 (en) | 2021-11-30 | 2024-10-09 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| AU2023219516A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| CA3251050A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE |
| EP4476228A1 (en) | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| CN119212986A (zh) | 2022-02-08 | 2024-12-27 | 弗特克斯药品有限公司 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
-
2021
- 2021-08-26 CN CN202180072946.7A patent/CN116547287B/zh active Active
- 2021-08-26 CR CR20230132A patent/CR20230132A/es unknown
- 2021-08-26 CA CA3190609A patent/CA3190609A1/en active Pending
- 2021-08-26 IL IL318169A patent/IL318169A/en unknown
- 2021-08-26 WO PCT/US2021/047754 patent/WO2022047031A1/en not_active Ceased
- 2021-08-26 AU AU2021333776A patent/AU2021333776A1/en active Pending
- 2021-08-26 JP JP2023513110A patent/JP7743504B2/ja active Active
- 2021-08-26 EP EP21773242.9A patent/EP4204423A1/en active Pending
- 2021-08-26 AR ARP210102407A patent/AR123355A1/es unknown
- 2021-08-26 IL IL300298A patent/IL300298B2/en unknown
- 2021-08-26 PE PE2023000722A patent/PE20231106A1/es unknown
- 2021-08-26 MX MX2023002269A patent/MX2023002269A/es unknown
- 2021-08-26 KR KR1020237008538A patent/KR20230057386A/ko active Pending
- 2021-08-26 UY UY0001039395A patent/UY39395A/es unknown
- 2021-08-26 US US17/446,135 patent/US11866446B2/en active Active
- 2021-08-26 BR BR112023003423A patent/BR112023003423A2/pt unknown
-
2023
- 2023-02-14 JO JOJO/P/2023/0035A patent/JOP20230035A1/ar unknown
- 2023-02-23 SA SA523442662A patent/SA523442662B1/ar unknown
- 2023-02-23 CL CL2023000536A patent/CL2023000536A1/es unknown
- 2023-02-28 DO DO2023000042A patent/DOP2023000042A/es unknown
- 2023-03-13 CO CONC2023/0003026A patent/CO2023003026A2/es unknown
- 2023-03-20 EC ECSENADI202320167A patent/ECSP23020167A/es unknown
- 2023-11-08 US US18/504,559 patent/US12421249B2/en active Active
-
2025
- 2025-09-10 JP JP2025150349A patent/JP2025183328A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539194A (ja) | 2023-09-13 |
| PE20231106A1 (es) | 2023-07-19 |
| KR20230057386A (ko) | 2023-04-28 |
| US20220106327A1 (en) | 2022-04-07 |
| IL300298B2 (en) | 2025-06-01 |
| JP2025183328A (ja) | 2025-12-16 |
| SA523442662B1 (ar) | 2025-05-26 |
| CN116547287B (zh) | 2025-09-26 |
| CA3190609A1 (en) | 2022-03-03 |
| CL2023000536A1 (es) | 2023-09-08 |
| IL300298A (en) | 2023-04-01 |
| JP7743504B2 (ja) | 2025-09-24 |
| AU2021333776A1 (en) | 2023-03-16 |
| EP4204423A1 (en) | 2023-07-05 |
| MX2023002269A (es) | 2023-05-16 |
| CN116547287A (zh) | 2023-08-04 |
| IL318169A (en) | 2025-03-01 |
| AR123355A1 (es) | 2022-11-23 |
| UY39395A (es) | 2022-03-31 |
| US11866446B2 (en) | 2024-01-09 |
| ECSP23020167A (es) | 2023-12-29 |
| WO2022047031A1 (en) | 2022-03-03 |
| JOP20230035A1 (ar) | 2023-02-14 |
| CO2023003026A2 (es) | 2023-03-17 |
| CR20230132A (es) | 2023-06-27 |
| US20240368180A1 (en) | 2024-11-07 |
| IL300298B1 (en) | 2025-02-01 |
| DOP2023000042A (es) | 2023-07-09 |
| US12421249B2 (en) | 2025-09-23 |
| TW202227456A (zh) | 2022-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023003423A2 (pt) | Inibidores de apol1 e métodos de uso destes | |
| UY40047A (es) | Inhibidores de apol1 y métodos de uso de estos | |
| CO2024012060A2 (es) | Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos | |
| CR20220062A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina | |
| CO2024012058A2 (es) | Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos | |
| BR0315381A (pt) | Composto ou um sal farmaceuticamente aceitável deste, composição farmacêutica, e, métodos para inibir a atividade da enzima dipeptidil peptidase-iv em um mamìfero em necessidade disto, para tratar diabetes em um mamìfero em necessidade disto, para tratar diabete não dependente de insulina (tipo 2) em um mamìfero em necessidade disto, para tratar hiperglicemia em um mamìfero em necessidade disto, para tratar a obesidade em um mamìfero em necessidade disto, para tratar um ou mais distúrbios de lipìdios selecionados do grupo de dislipidemia, hiperlipidemia, hipertrigliceridemia, hipercolesterolemia, hdl baixo e ldl alto em um mamìfero em necessidade disto, e para tratar em um mamìfero em necessidade disto uma ou mais condições | |
| BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| BR112012010124A2 (pt) | composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| BR112021018254A8 (pt) | Derivados de nicorandil | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BRPI0514390A (pt) | enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica | |
| BRPI0514868A (pt) | composto, composição farmacêutica, uso de um composto, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, para tratar ou prevenir cáncer em um animal de sangue quente, e para tratar doenças, e, processo para preparar um composto | |
| BR112022005706A2 (pt) | Inibidores de 1,6-naftiridina substituída de cdk5 | |
| MX2025001062A (es) | Derivados de heteroaril sulfonamida biciclicos sustituidos para el tratamiento del cancer | |
| BR112021006424A2 (pt) | inibidores de quinase tyk2 | |
| BR0209985A (pt) | Composto e método para o tratamento de um paciente | |
| GEAP202416568A (en) | Triazolone derivative salt as neutrophil elastase inhibitor | |
| WO2022169834A3 (en) | Small molecule inhibitors of grp78 and uses thereof | |
| EA202192414A1 (ru) | Соединения-ингибиторы натрий-водородного обменника 3 | |
| BRPI0407350A (pt) | Combinações farmacêuticas compreendendo corticóides e imunosupressores para tratamento de doenças resistentes aos corticóides e/ou inibidores de calcineurina | |
| BR112022006184A2 (pt) | Tratamento baseado em biomarcadores da glomeruloesclerose segmentar focal e doença renal diabética |